Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study. (December 2022)
- Record Type:
- Journal Article
- Title:
- Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study. (December 2022)
- Main Title:
- Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study
- Authors:
- Murarasu, Anne
Guettrot-Imbert, Gaëlle
Le Guern, Véronique
Yelnik, Cécile
Queyrel, Viviane
Schleinitz, Nicolas
Ferreira-Maldent, Nicole
Diot, Elisabeth
Urbanski, Geoffrey
Pannier, Emmanuelle
Lazaro, Estibaliz
Souchaud-Debouverie, Odile
Orquevaux, Pauline
Belhomme, Nicolas
Morel, Nathalie
Chauvet, Elodie
Maurier, François
Le Besnerais, Maëlle
Abisror, Noemie
Goulenok, Tiphaine
Sarrot-Reynauld, Françoise
Deroux, Alban
Pasquier, Elisabeth
de Moreuil, Claire
Bezanahary, Holy
Pérard, Laurent
Limal, Nicolas
Langlois, Vincent
Calas, Anne
Godeau, Bertrand
Lavigne, Christian
Hachulla, Eric
Cohen, Fleur
Benhamou, Ygal
Raffray, Loïc
de Menthon, Mathilde
Tieulié, Nathalie
Poindron, Vincent
Mouthon, Luc
Larosa, Maddalena
Eléfant, Elisabeth
Sentilhes, Loic
Molto, Anna
Deneux-Tharaux, Catherine
Costedoat-Chalumeau, Nathalie
Azzi, Emmanuel
Banneville, Béatrice
Baudet, Antoine
Beaudouin-Bazire, Constance
Belizna, Cristina
Belkhir, Rakiba
Berezne, Alice
Berthoux, Emilie
Berthier, Sabine
Biale, Lisa
Bienvenu, Boris
Blanchard-Delaunay, Claire
Cathebras, Pascal
Cazalets, Claire
Chaigne, Benjamin
Chandesris, Olivia
Chatelais, Jérémy
Chatelus, Emmanuel
Coquerelle, Pascal
Couderc, Marion
Delforge, Juliette
Denis, Amélie
Desouches, Sandra
Dieudé, Philippe
Direz, Guillaume
Driessen, Marine
Du Thanh, Aurélie
Dunogeant, Laetitia
Durant, Cécile
Durieu, Isabelle
Fabre, Marc
Fain, Olivier
Flipo, René-Marc
Frazier, Aline
Froissart, Antoine
Georgin-Lavialle, Sophie
Gervais, Elisabeth
Gompel, Anne
Gossec, Laure
Goupille, Phillipe
Grange, Claire
Guillaud-Danis, Constance
Hummel, Aurélie
Jallouli, Moez
Jego, Patrick
Jobard, Stéphane
Josselin-Mahr, Laurence
Jourde-Chiche, Noémie
Korganow, Anne-Sophie
Lambert, Marc
Lariviere, Delphine
Larroche, Claire
Lartigau-Roussin, Céline
Latourte, Augustin
Le Gallou, Thomas
Leroux, Gaëlle
Levesque, Hervé
Lioté, Frédéric
London, Jonathan
Loustau, Valentine
Maheu, Emmanuel
Mahevas, Matthieu
Maillard, Hélène
Mariette, Xavier
Marotte, Hubert
Martin-Silva, Nicolas
Martis, Nihal
Masseau, Agathe
Mekinian, Arsène
Melboucy-Belkhir, Sara
Michaud, Martin
Michel, Marc
Morati-Hafsaoui, Chafika
Nizard, Jacky
Ora, Jérémy
Pennaforte, Jean-Loup
Perlat, Antoinette
Petit Bauer, Hélène
Pillebout, Evangeline
Piot, Jean-Maxime
Portier, Agnès
Pugnet, Gregory
Redondin, Manon
Regent, Alexis
Richez, Christophe
Roriz, Mélanie
Sailler, Laurent
Sauvêtre, Gaëtan
Savey, Léa
Sobanski, Vincent
Sordet, Christelle
Soubrier, Martin
Stankovic Stojanovic, Katia
Thomas, Thierry
Timsit, Marie-Agnès
Tsatsaris, Vassilis
… (more) - Abstract:
- Summary: Background: Prospective data about the risks of thrombotic and severe haemorrhagic complications during pregnancy and post partum are unavailable for women with antiphospholipid syndrome. We aimed to assess thrombotic and haemorrhagic events in a prospective cohort of pregnant women with antiphospholipid syndrome. Methods: This multicentre, prospective, observational study was done at 76 centres in France. To be eligible for this study, women had to have diagnosis of antiphospholipid syndrome; have conceived before April 17, 2020; have an ongoing pregnancy that had reached 12 weeks of gestation; and be included in the study before 18 weeks of gestation. Exclusion criteria were active systemic lupus erythematosus nephropathy, or a multifetal pregnancy. Severe haemorrhage was defined as the need for red blood cell transfusion or maternal intensive care unit admission because of bleeding or invasive procedures, defined as interventional radiology or surgery, to control bleeding. The GR2 study is registered with ClinicalTrials.gov, NCT02450396 . Findings: Between May 26, 2014, and April 17, 2020, 168 pregnancies in 27 centres met the inclusion criteria for the study. 89 (53%) of 168 women had a history of thrombosis. The median term at inclusion was 8 weeks gestation. 16 (10%) of 168 women (95%CI 5–15) had a thrombotic (six [4%] women; 95% CI 1–8) or severe haemorrhagic event (12 [7%] women; 95% CI 4–12). There were no deaths during the study. The main risk factors forSummary: Background: Prospective data about the risks of thrombotic and severe haemorrhagic complications during pregnancy and post partum are unavailable for women with antiphospholipid syndrome. We aimed to assess thrombotic and haemorrhagic events in a prospective cohort of pregnant women with antiphospholipid syndrome. Methods: This multicentre, prospective, observational study was done at 76 centres in France. To be eligible for this study, women had to have diagnosis of antiphospholipid syndrome; have conceived before April 17, 2020; have an ongoing pregnancy that had reached 12 weeks of gestation; and be included in the study before 18 weeks of gestation. Exclusion criteria were active systemic lupus erythematosus nephropathy, or a multifetal pregnancy. Severe haemorrhage was defined as the need for red blood cell transfusion or maternal intensive care unit admission because of bleeding or invasive procedures, defined as interventional radiology or surgery, to control bleeding. The GR2 study is registered with ClinicalTrials.gov, NCT02450396 . Findings: Between May 26, 2014, and April 17, 2020, 168 pregnancies in 27 centres met the inclusion criteria for the study. 89 (53%) of 168 women had a history of thrombosis. The median term at inclusion was 8 weeks gestation. 16 (10%) of 168 women (95%CI 5–15) had a thrombotic (six [4%] women; 95% CI 1–8) or severe haemorrhagic event (12 [7%] women; 95% CI 4–12). There were no deaths during the study. The main risk factors for thrombotic events were lupus anticoagulant positivity at inclusion (six [100%] of six women with thrombosis vs 78 [51%] of 152 of those with no thrombosis; p=0·030) and placental insufficiency (four [67%] of six women vs 28 [17%] of 162 women; p=0·013). The main risk factors for severe haemorrhagic events were pre-existing maternal hypertension (four [33%] of 12 women vs 11 [7%] of 156 women; p=0·014), lupus anticoagulant positivity at inclusion (12 [100%] of 12 women vs 72 [49%] of 146 women; p<0·0001) and during antiphospholipid history (12 [100%] of 12 women vs 104 [67%] of 156 women; p=0·019), triple antiphospholipid antibody positivity (eight [67%] of 12 women vs 36 [24%] of 147 women; p=0·0040), placental insufficiency (five [42%] of 12 women vs 27 [17%] of 156 women; p=0·038), and preterm delivery at 34 weeks or earlier (five [45%] of 11 women vs 12 [8%] of 145 women; p=0·0030). Interpretation: Despite treatment adhering to international recommendations, a proportion of women with antiphospholipid syndrome developed a thrombotic or severe haemorrhagic complication related to pregnancy, most frequently in the post-partum period. Lupus anticoagulant and placental insufficiency were risk factors for these life-threatening complications. These complications are difficult to prevent, but knowledge of the antenatal characteristics associated with them should increase awareness and help physicians manage these high-risk pregnancies. Funding: Lupus France, association des Sclérodermiques de France, association Gougerot Sjögren, Association Francophone contre la Polychondrite chronique atrophiante, AFM-Telethon, the French Society of Internal Medicine and Rheumatology, Cochin Hospital, the French Health Ministry, FOREUM, the Association Prix Veronique Roualet, and UCB. … (more)
- Is Part Of:
- Lancet. Volume 4:Number 12(2022)
- Journal:
- Lancet
- Issue:
- Volume 4:Number 12(2022)
- Issue Display:
- Volume 4, Issue 12 (2022)
- Year:
- 2022
- Volume:
- 4
- Issue:
- 12
- Issue Sort Value:
- 2022-0004-0012-0000
- Page Start:
- e842
- Page End:
- e852
- Publication Date:
- 2022-12
- Subjects:
- Rheumatology -- periodicals
616.72305 - Journal URLs:
- https://www.thelancet.com/journals/lanrhe/issues#decade=loi_decade_201 ↗
https://www.sciencedirect.com/journal/the-lancet-rheumatology ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/S2665-9913(22)00308-3 ↗
- Languages:
- English
- ISSNs:
- 2665-9913
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24805.xml